Trypanosoma cruzi cysteine proteases, acting at the interface between the vascular and immune systems, influence pathogenic outcome in experimental Chagas disease

Open Parasitology Journal

Volumn 4, Issue SPEC. ISS.1, 2010, Pages 60-71

  Scharfstein, Julio ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Chagas disease; Chagasin; Cruzipain; Kinins; Toll like 2 receptors; Trypanosoma Cruzi

Indexed keywords

ALPHA CHEMOKINE; BRADYKININ RECEPTOR; CALCIUM ION; CHAGASIN; CHEMOKINE RECEPTOR CXCR2; CRUZIPAIN; CYSTEINE PROTEINASE; DIPEPTIDYL CARBOXYPEPTIDASE; G PROTEIN COUPLED BRADYKININ RECEPTOR; G PROTEIN COUPLED RECEPTOR; KININ; KININOGEN; PROTEOHEPARAN SULFATE; TOLL LIKE RECEPTOR 2; UNCLASSIFIED DRUG;

ARTICLE; CARDIOVASCULAR CELL; CARDIOVASCULAR SYSTEM; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL TYPE; CELLULAR IMMUNITY; CHAGAS DISEASE; CHRONIC DISEASE; DENDRITIC CELL; EDEMA; EFFECTOR CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; HEART DISEASE; HOST CELL; HOST PARASITE INTERACTION; HUMAN; IMMUNE SYSTEM; IMMUNOSTIMULATION; INFLAMMATION; LEUKOCYTE ACTIVATION; LYMPHOID TISSUE; MACROPHAGE FUNCTION; METABOLIC REGULATION; MICROVASCULATURE; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NONHUMAN; PARACRINE SIGNALING; PARASITE VIRULENCE; PARASITISM; PATHOGENESIS; PHAGOCYTE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN CARBOHYDRATE INTERACTION; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; PROTEIN TARGETING; PROTEIN TRANSPORT; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TISSUE CULTURE; TRYPANOSOMA CRUZI; TRYPOMASTIGOTE; VASCULAR ENDOTHELIUM;

TRYPANOSOMA CRUZI;

EID: 80052170899     PISSN: None     EISSN: 18744214     Source Type: Journal    
DOI: 10.2174/1874421401004010060     Document Type: Article

References (129)

1. Reis DD, Jones EM, Tostes S, Gazzinelli G, Colley DG, McCurley T. Characterization of inflammatory infiltrates in chonic chagasic myocardial lesions: presence of TNF-alpha+ cells and dominance of Granzyme A+, CD8+ lymphocytes. Am J Trop Med Hyg 1993; 43: 637-44.
2. Jones EM, Colley DG, Tostes S, Lopes ER, Vnencak-Jones CL, McCurley TL. Amplification of a Trypanosoma cruzi DNA sequence from inflammatory lesions in human chagasic cardiomyopathy. Am J Trop Med Hyg 1993; 48(3): 348-57.
3. + T cells with the presence of Trypanosoma cruzi antigens in chronic, human, chagasic myocarditis. Am J Trop Med Hyg 1997; 56(5): 485-89.
4. Palomino SA, Aiello VD, Higuchi ML. Systematic mapping of hearts from chronic chagasic patients: the association between the occurrence of histopathological lesions and Trypanosoma cruzi antigens. Ann Trop Med Parasitol 2000; 94(6): 571-79.
5. Tarleton R. Parasite persistence in the etiology of Chagas disease. Int J Parasitol 2004; 31: 550-54.
6. Leon JS, Engman DM. The significance of autoimmunity in the pathogenesis of Chagas heart disease. Front Biosci 2003; 8: e315-22.
7. Ribeiro-Dos-Santos R, Mengel JO, Postol E, et al. A heart-specific CD4+ T-cell line obtained from a chronic chagasic mouse induces carditis in heart-immunized mice and rejection of normal heart transplants in the absence of Trypanosoma cruzi. Parasite Immunol 2001; 23(2): 93-101.
8. Scharfstein J, Morrot A. A role for extracellular amastigotes in the immunopathology of Chagas disease. Mem Inst Oswaldo Cruz 1999; 94(1): 51-63.
9. Freire-de-Lima CG, Nascimento DO, Soares MB, et al. Uptake of apoptotic cells drives the growth of pathogenic trypanosome in macrophages. Nature 2000; 403(6766): 194-203.
10. Laucella SA, Postan M, Martin D, et al. Frequency of interferongamma -producing T cells specific for Trypanosoma cruzi inversely correlates with disease severity in chronic human Chagas disease. J Infect Dis 2004; 189(5): 909-18.
11. + T central memory response in chronic Chagas disease. Nat Med 2008; 14(5): 542-50.
12. Macedo AM, Pena SD. Genetic variability of Trypanosoma cruzi: implications for the pathogenesis of chagas disease. Parasitol Today 1998; 14(3): 119-24.
13. Fonseca SG, Moins-Teisserenc H, Clave E, et al. Identification of multiple HLA-A*0201-restricted cruzipain and FL-160 CD8+ epitopes recognized by T cells from chronically Trypanosoma cruziinfected patients. Microbes Infect 2005; 7(4): 688-97.
14. Gomes JA, Bahia-Oliveira LM, Rocha MO, Martins-Filho OA, Gazzinelli G, Correa-Oliveira R. Evidence that development of severe cardiomyopathy in human Chagas disease is due to a Th1specific immune response. Infect Immun 2003; 71(3): 1185-93.
15. Costa GC, da Costa Rocha MO, Moreira PR, et al. Functional IL10 gene polymorphism is associated with Chagas disease cardiomyopathy. J Infect Dis 2009; 199(3): 451-4.
16. Rossi MA. Microvascular changes as a cause of chronic cardiomyopathy in Chagas' disease. Am Heart J 1990; 10: 233-36.
17. Morris SA, Tanowitz H, Wittner M, Bilezikian JP. Pathophysiological insights into the cardiomyopathy of Chagas' disease. Circulation 1990; 82: 1900-10.
18. Tanowitz HB, Burns ER, Sinha AK, et al. Enhanced platelet adherence and aggregation in Chagas' disease: a potential pathogenic mechanism for cardiomyopathy. Am J Trop Med Hyg 1990; 43(3): 274-81.
19. Higuchi ML, Fukasawa S, De Brito T, Parzianello LC, Bellotti G, Ramires JÁ. Different microcirculatory and interstitial matrix patterns in idiopathic dilated cardiomyopathy and Chagas' disease: a three dimensional confocal microscopy study. Heart 1999; 82(3): 279-85.
20. Tanowitz HB, Huang H, Jelicks LA, et al. Role of endothelin 1 in the pathogenesis of chronic chagasic heart disease. Infect Immun 2005; 73(4): 2496-503.
21. Hassan GS, Mukherjee S, Nagajyothi F, et al. Trypanosoma cruzi infection induces proliferation of vascular smooth muscle cells. Infect Immun 2006; 74(1): 152-9.
22. Libby P, Alroy J, Pereira ME. A neuraminidase from Trypanosoma cruzi removes sialic acid from the surface of mammalian myocardial and endothelial cells. J Clin Invest 1986; 77(1): 127-35.
23. Previato JO, Andrade AF, Pessolani MC, Mendonça-Previato L. Incorporation of sialic acid into Trypanosoma cruzi macromolecules. A proposal for a new metabolic route. Mol Biochem Parasitol 1985; 16(1): 85-96.
24. Schenkman S, Jiang MS, Hart GW, Nussenzweig V. A novel cell surface trans-sialidase of Trypanosoma cruzi generates a stagespecific epitope required for invasion of mammalian cells. Cell 1991; 65(7): 1117-25.
25. Todeschini AR, Girard MF, Wieruszeski JM, et al. Trans-Sialidase from Trypanosoma cruzi binds host T-lymphocytes in a lectin manner. J Biol Chem 2002; 277(48): 45962-68.
26. Dias WB, Fajardo FD, Graça-Souza AV, et al. Endothelial cell signalling induced by trans-sialidase from Trypanosoma cruzi. Cell Microbiol 2008; 10(1): 88-99.
27. Affranchino JL, Ibañez CF, Luquetti AO, et al. Identification of a Trypanosoma cruzi antigen that is shed during the acute phase of Chagas' disease. Mol Biochem Parasitol 1989; 34(3): 221-8.
28. Andrade ZA, Andrade SG, Correa R, Sadigursky M, Ferrans VJ. Myocardial changes in acute Trypanosoma cruzi infection. Ultrastructural evidence of immune damage and the role of microangiopathy. Am J Pathol 1994; 144(6): 1403-11.
29. Duthie MS, Cetron MS, Van Voorhis WC, Kahn SJ. Trypanosoma cruzi-infected individuals demonstrate varied antibody responses to a panel of trans-sialidase proteins encoded by SA85-1 genes. Acta Trop 2005; 3(3): 317-29.
30. Ashton AW, Mukherjee S, Nagajyothi FN, et al. Thromboxane A2 is a key regulator of pathogenesis during Trypanosoma cruzi infection. J Exp Med 2007; 204(4): 929-40.
31. Gomes MT, Monteiro RQ, Grillo LA, et al. Platelet-activating factor-like activity isolated from Trypanosoma cruzi. Int J Parasitol 2006; 36(2): 165-73.
32. Ropert C, Gazzinelli RT. Innate recognition, cell signaling and proinflammatory responses during infection with Trypanosoma cruzi. In: Denkers EY, Gazzinelli RT, Eds. Protozoans in macrophages (Texas), Austin: Landes Biosciences 2007; pp. 49-66.
33. Campos MA, Almeida IC, Takeuchi O, et al. Activation of Tolllike receptor-2 by glycosylphosphatidylinositol anchors from a protozoan parasite. J Immunol 2001; 167: 416-23.
34. Oliveira AC, Peixoto JR, Arruda LB, et al. Expression of functional TLR4 confers proinflammatory responsiveness to Trypanosoma cruzi glycoinositolphospholipids and higher resistance to infection with T. cruzi. J Immunol 2004; 173: 5688-96.
35. Ouaissi A, Guilvard E, Delneste Y, et al. The Trypanosoma cruzi Tc52-released protein induces human dendritic cell maturation, signals via Toll-like receptor 2, and confers protection against lethal infection. J Immunol 2002; 168: 6366-74.
36. Bafica A, Santiago HC, Goldszmid R, Ropert C, Gazzinelli RT, Sher A. Cutting edge: TLR9 and TLR2 signaling together account for MyD88-dependent control of parasitemia in Trypanosoma cruzi infection. J Immunol 2006; 177: 3515-19.
37. Almeida IC, Gazzinelli RT. Proinflammatory activity of glycosylphosphatidylinositol anchors derived from Trypanosoma cruzi: structural and functional analyses. J Leukoc Biol 2001; 70: 467-77.
38. Serrano AA, Schenkman S, Yoshida N, Mehlert A, Richardson JM, Ferguson MA. The lipid structure of the glycosylphosphatidylinositol-anchored mucin-like sialic acid acceptors of Trypanosoma cruzi changes during parasite differentiation from epimastigotes to infective metacyclic trypomastigote forms. J Biol Chem 1995; 270(45): 27244-53.
39. Tarleton RL. Immune system recognition of Trypanosoma cruzi. Curr Opin Immunol 2007; 19: 430-34.
40. Peterson CA, Krumholz A, Burleigh BA. Toll-like receptor 2 regulates Interleukin-IB-dependent cardiomyocytes hypertrophy triggered by Trypanosoma cruzi. Infection Immunity 2005; 73(10): 6974-80.
41. Coelho PS, Klein A, Talvani A, et al. Glycosylphosphatidylinositol-anchored mucin-like glycoproteins isolated from Trypanosoma cruzi trypomastigotes induce in vivo leukocyte recruitment dependent on MCP-1 production by IFN- -primed-macrophages. J Leukocyte Biol 2002; 71: 837-44.
42. Cazzulo JJ, Stoka V, Turk V. Cruzipain, the major cysteine proteinase from the protozoan Trypanosoma cruzi. Bio Chem 1997; 378(1): 1-10.
43. McKerrow JH. Development of cysteine protease inhibitors as chemotherapy for parasitic diseases: insight on safety, target validation and mechanism of action. Int J Parasitol 1999; 29(6): 833-37.
44. Bryant C, Kerr ID, Debnath M, et al. Novel non-peptidic vinylsulfones targeting the S2 and S3 subsites of parasite cysteine proteases. Bioorg Med Chem Lett 2009; 19(21): 6218-21.
45. Duschak VG, Couto AS. Cruzipain,the major cysteine protease of Trypanosoma cruzi: a sulfated glycoprotein antigen as relevant candidate for vaccine development and drug target. A review. Curr Med Chem 2009; 16: 3174-202.
46. Mendonça-Previato L, Gorin PA, Braga AF, Scharfstein J, Previato JO. Chemical structure and antigenic aspects of complexes obtained from epimastigotes of Trypanosoma cruzi. Biochemistry 1983; 22(21): 4980-87.
47. Scharfstein J, Rodrigues MM, Alves CA, et al. Trypanosoma cruzi: description of a highly purified surface antigen defined by human antibodies. J Immunol 1983; 131(2): 972-76.
48. Scharfstein J, Luquetti A, Murta AC, et al. Chagas' disease: serodiagnosis with purified Gp25 antigen. Am J Trop Med Hyg 1985; 34(6): 1153-60.
49. Scharfstein J, Schechter M, Senna M, et al. Trypanosoma cruzi: characterization and isolation of a 57/51,000 m.w. surface glycoprotein (GP57/51) expressed by epimastigotes and bloodstream trypomastigotes. J Immunol 1986; 137(4): 1336-41.
50. Cazzulo JJ, Cazzulo Franke MC, Martinez J, et al. Some kinetic properties of a cysteine proteinase (cruzipain) from Trypanosoma cruzi. Biochim Biophys Acta 1990; 1037(2): 186-91.
51. Murta AC, Persechini PM, Padron Td, et al. Structural and functional identification of GP57/51 antigen of Trypanosoma cruzi as a cysteine proteinase. Mol Biochem Parasitol 1990; 43(1): 27-38.
52. Cazzulo JJ, Couso R, Raimondi A, et al. Further characterization and partial amino acid sequence of a cysteine proteinase from Trypanosoma cruzi. Mol Biochem Parasitol 1989; 33(1): 33-41.
53. Eakin AE, Bouvier J, Sakanari JA, Craik CS, McKerrow JH. Amplification and sequencing of genomic DNA fragments encoding cysteine proteases from protozoan parasites. Mol Biochem Parasitol 1990; 39(1): 1-8.
54. Aslund L, Henriksson J, Campetella O, et al. The C-terminal extension of the major cysteine proteinase (cruzipain) from Trypanosoma cruzi. Mol Biochem Parasitol 1991; 45(2): 345-47.
55. Cazzulo JJ, Martínez J, Parodi AJ, Wernstedt C, Hellman U. On the post-translational modifications at the C-terminal domain of the major cysteine proteinase (cruzipain) from Trypanosoma cruzi. FEMS Microbiol Lett 1992; 79(1-3): 411-16.
56. Hellman U, Wernstedt C, Cazzulo JJ. Self-proteolysis of the cysteine proteinase, cruzipain, from Trypanosoma cruzi gives a major fragment corresponding to its carboxy-terminal domain. Mol Biochem Parasitol 1991; 44(1): 15-21.
57. Eakin AE, Mills AA, Harth G, et al. The sequence, organization, and expression of the major cysteine protease (cruzain) from Trypanosoma cruzi. J Biol Chem 1992; 267(11): 7411-720.
58. Parodi AJ, Labriola C, Cazzulo JJ. The presence of complex-type oligosaccharides at the C-terminal domain glycosylation site of some molecules of cruzipain. Mol Biochem Parasitol 1995; 69(2): 247-55.
59. Arnholdt AC, Piuvezam MR, Russo DM, et al. Analysis and partial epitope mapping of human T cell responses to Trypanosoma cruzi cysteinyl proteinase. J Immunol 1993; 151(6): 3171-79.
60. Barboza M, Duschak VG, Fukuyama Y, et al. Structural analysis of the N-glycans of the major cysteine proteinase of Trypanosoma cruzi. Identification of sulfated high-mannose type oligosaccharides. FEBS J 2005; 272(15): 3803-15.
61. Campetella O, Henriksson J, Aslund L, Frasch AC, Pettersson U, Cazzulo JJ. The major cysteine proteinase (cruzipain) from Trypanosoma cruzi is encoded by multiple polymorphic tandemly organized genes located on different chromosomes. Mol Biochem Parasitol 1992; 50(2): 225-34.
62. Meirelles MN, Juliano L, Carmona E, et al. Inhibitors of the major cysteinyl proteinase (GP57/51) impair host cell invasion and arrest the intracellular development of Trypanosoma cruzi in vitro. Mol Biochem Parasitol 1992; 52(2): 175-84.
63. Harth G, Andrews N, Mills AA, Engel JC, Smith R, McKerrow JH. Peptide-fluoromethyl ketones arrest intracellular replication and intercellular transmission of Trypanosoma cruzi. Mol Biochem Parasitol 1993; 58(1): 17-24.
64. Franke de Cazzulo BM, Martínez J, North MJ, Coombs GH, Cazzulo JJ. Effects of proteinase inhibitors on the growth and differentiation of Trypanosoma cruzi. FEMS Microbiol Lett 1994; 124(1): 81-6.
65. McGrath ME, Eakin AE, Engel JC, et al. The crystal structure of cruzain: a therapeutic target for Chagas' disease. J Mol Biol 1995; 247(2): 251-9.
66. Roush WR, Cheng J, Knapp-Reed B, et al. Potent second generation vinyl sulfonamide inhibitors of the trypanosomal cysteine protease cruzain. Bioorg Med Chem Lett 2001; 11(20): 2759-62.
67. Engel JC, Doyle PS, Hsieh I, et al. Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection. J Exp Med 1998; 188(4): 725-34.
68. Doyle PS, Zhou YM, Engel JC, McKerrow JH. A cysteine protease inhibitor cures Chagas' disease in an immunodeficient-mouse model of infection. Antimicrob Agents Chemother 2007; 51(11): 3932-39.
69. Barr SC, Warner KL, Kornreic BG, et al. A cysteine protease inhibitor protects dogs from cardiac damage during infection by Trypanosoma cruzi. Antimicrob Agents Chemother 2005; 49(12): 5160-61.
70. Caffrey CR, Steverding D. Kinetoplastid papain-like cysteine peptidases. Mol Biochem Parasitol 2009; 167(1): 12-19.
71. Lima AP, Tessier DC, Thomas DY, Scharfstein J, Storer AC, Vernet T. Identification of new cysteine protease gene isoforms in Trypanosoma cruzi. Mol Biochem Parasitol 1994; 67(2): 333-38.
72. Lima AP, dos Reis FC, Serveau C, et al. Cysteine protease isoforms from Trypanosoma cruzi, cruzipain 2 and cruzain, present different substrate preference and susceptibility to inhibitors. Mol Biochem Parasitol 2001; 114(1): 41-52.
73. dos Reis FC, Júdice WA, Juliano MA, Juliano L, Scharfstein J, Lima AP. The substrate specificity of cruzipain 2, a cysteine protease isoform from Trypanosoma cruzi. FEMS Microbiol Lett 2006; 259(2): 215-20.
74. El-Sayed NM, Myler PJ, Bartholomeu DC, et al. The genome sequence of Trypanosoma cruzi, etiologic agent of Chagas disease. Science 2005; 309(5733): 409-15.
75. Kosec G, Alvarez V, Cazzulo JJ. Cysteine proteinases of Trypanosoma cruzi: from digestive enzymes to programmed cell death mediators. Biocell 2006; 30(3): 479-90.
76. Nóbrega OT, Santos Silva MA, Teixeira AR, Santana JM. Cloning and sequencing of tccb, a gene encoding a Trypanosoma cruzi cathepsin B-like protease. Mol Biochem Parasitol 1998; 97(1-2): 235-40.
77. Yong V, Schmitz V, Vannier-Santos MA, et al. Altered expression of cruzipain and a cathepsin B-like target in a Trypanosoma cruzi cell line displaying resistance to synthetic inhibitors of cysteineproteinases. Mol Biochem Parasitol 2000; 109(1): 47-59.
78. Piras MM, Henriquez D, Piras R. The effect of proteolytic enzymes and protease inhibitors on the interaction Trypanosoma cruzifibroblasts. Mol Biochem Parasitol 1985; 14(2): 151-63.
79. 2+ signaling in mammalian cells. J Cell Biol 1997; 136(3): 609-20.
80. Burleigh BA, Woolsey AM. Cell signalling and Trypanosoma cruzi invasion. Cell Microbiol 2002; 4(11): 701-11.
81. Tardieux I, Webster P, Ravesloot J, et al. Lysosome recruitment and fusion are early events required for trypanosome invasion of mammalian cells. Cell 1992; 71(7): 1117-30.
82. Andrews NW. Regulated secretion of conventional lysosomes. Trends Cell Biol 2000; 10: 316-21.
83. Leite MF, Moyer MS, Andrews NW. Expression of the mammalian calcium signaling response to Trypanosoma cruzi in Xenopus laevis oocytes. Mol Biochem Parasitol 1998; 92(1): 1-13.
84. Scharfstein J, Schmitz V, Morandi V, et al. Host cell invasion by Trypanosoma cruzi is potentiated by activation of bradykinin B(2) receptors. J Exp Med 2000; 192(9): 1289-300.
85. Todorov AG, Andrade D, Pesquero JB, et al. Trypanosoma cruzi induces edematogenic responses in mice and invades cardiomyocytes and endothelial cells in vitro by activating distinct kinin receptor (B1/B2) subtypes. FASEB J 2003; 17: 73-5.
86. Ming M, Ewen ME, Pereira ME. Trypanosome invasion of mammalian cells requires activation of the TGF beta signaling pathway. Cell 1995; 82(2): 287-96.
87. Waghabi MC, Keramidas M, Feige JJ, Araujo-Jorge TC, Bailly S. Activation of transforming growth factor beta by Trypanosoma cruzi. Cell Microbiol 2005; 7(4): 511-7.
88. Waghabi MC, de Souza EM, de Oliveira GM, et al. Pharmacological inhibition of transforming growth factor beta signaling decreases infection and prevents heart damage in acute Chagas' disease. Antimicrob Agents Chemother 2009; 53(11): 4694-701.
89. Bastos IM, Grellier P, Martins NF, et al. Molecular, functional and structural properties of the prolyl oligopeptidase of Trypanosoma cruzi (POP Tc80), which is required for parasite entry into mammalian cells. Biochem J 2005; 388(1): 29-38.
90. Aparicio IM, Scharfstein J, Lima APCA. A new cruzipaindependent pathway of human cell invasion by Trypanosoma cruzi requiring trypomastigote membranes. Infect Immun 2004; 72: 5892-02
91. Briones MR, Egima CM, Eichinger D, Schenkman S. Transsialidase genes expressed in mammalian forms of Trypanosoma cruzi evolved from ancestor genes expressed in insect forms of the parasite. J Mol Evol 1995; 41(2): 120-31.
92. Freitas-Junior LH, Briones MR, Schenkman S. Two distinct groups of mucin-like genes are differentially expressed in the developmental stages of Trypanosoma cruzi. Mol Biochem Parasitol 1998; 93(1): 101-14.
93. Alves MJ, Colli W. Role of the gp85/trans-sialidase superfamily of glycoproteins in the interaction of Trypanosoma cruzi with host structures. Subcell Biochem 2008; 47: 58-69
94. Trocoli Torrecilhas AC, Tonelli RR, Pavanelli WR, et al. Trypanosoma cruzi: parasite shed vesicles increase heart parasitism and generate an intense inflammatory response. Microbes Infect 2009; 11(1): 29-39.
95. Magdesian MH, Giordano R, Ulrich H, et al. Infection by Trypanosoma cruzi. Identification of a parasite ligand and its host cell receptor. J Biol Chem. 2001; 276(22): 19382-9.
96. Magdesian MH, Tonelli RR, Fessel MR, et al. A conserved domain of the gp85/trans-sialidase family activates host cell extracellular signal-regulated kinase and facilitates Trypanosoma cruzi infection. Exp Cell Res 2007; 313(1): 210-8.
97. Giordano R, Fouts DL, Tewari D, Colli W, Manning JE, Alves MJ. Cloning of a surface membrane glycoprotein specific for the infective form of Trypanosoma cruzi having adhesive properties to laminin. J Biol Chem 1999; 274(6): 3461-8.
98. Tomas AM, Kelly JM. Stage-regulated expression of cruzipain, the major cysteine protease of Trypanosoma cruzi is independent of the level of RNA. Eur J Biochem 1996; 76(1-2): 91-103.
99. Monteiro AC, Abrahamson M, Lima AP, Vannier-Santos MA, Scharfstein J. Identification, characterization and localization of chagasin, a tight-binding cysteine protease inhibitor in Trypanosoma cruzi. J Cell Sci 2001; 114(Pt 21): 3933-42.
100. Santos CC, Santanna C, Terres A, et al. Chagasin, the endogenous cysteine-protease inhibitor of Trypanosoma cruzi, modulates parasite differentiation and invasion of mamalian cells. J Cell Sci 2005; 118: 901-15.
101. Sanderson SJ, Westrop GD, Scharfstein J, et al. Functional conservation of a natural cysteine peptidase inhibitor in protozoan and bacterial pathogens. FEBS Lett 2003; 542: 12-6.
102. Rigden DJ, Mosolov VV, Galperin MY. Sequence conservation in the chagasin family suggests a common trend in cysteine proteinase binding by unrelated protein inhibitors. Protein Sci 2002; 11: 971-77.
103. Salmon D, Aido-Machado R, Diehl A, et al. Solution structure and backbone dynamics of the Trypanosoma cruzi cysteine protease inhibitor chagasin. J Mol Biol 2006; 357: 1511-1521.
104. Wang SX, Pandey KC, Scharfstein J, et al. The structure of chagasin in complex with a cysteine protease clarifies the binding mode and evolution of an inhibitor family. Structure 2007; 15(5): 535-43.
105. Redzynia I, Ljunggren A, Bujacz A, Abrahamson M, Jaskolski M, Bujacz G. Crystal structure of the parasite inhibitor chagasin in complex with papain allows identification of structural requirements for broad reactivity and specificity determinants for target proteases. FEBS J 2009; 276(3): 793-806.
106. Smith BO, Picken NC, Westrop GD, Bromek K, Mottram JC, Coombs GH. The structure of Leishmania mexicana ICP provides evidence for convergent evolution of cysteine peptidase inhibitors. J Biol Chem 2006; 281(9): 5821-8.
107. Engel JC, Doyle PS, Palmer J, Hsieh I, Bainton DF, McKerrow JH. Cysteine protease inhibitors alter Golgi complex ultrastructure and function in Trypanosoma cruzi. J Cell Sci 1998; 11(Pt 5): 597-606.
108. Scharfstein J, Lima AP. Roles of naturally occurring protease inhibitors in the modulation of host cell signaling and cellular invasion by Trypanosoma cruzi. Subcell Biochem 2008; 47: 140-54.
109. Brooks DR, Tetley L, Coombs GH, et al. Processing and trafficking of cysteine proteases in Leishmania mexicana. J Cell Sci 2000; 113: 4035-41
110. Bhoola KD, Figueroa CD, Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev 1992; 44: 1-80.
111. Blaukat A. Structure and signalling pathways of kinin receptors. Andrologia 2003; 35: 17-23.
112. Scharfstein J, Monteiro AC, Schmitz V, Svensjö E. Angiotensinconverting enzyme limits inflammation elicited by Trypanosoma cruzi cysteine proteases: a peripheral mechanism regulating adaptive immunity via the innate kinin pathway. Biol Chem 2008; 389(8): 1015-24.
113. Imamura T, Pike RN, Potempa J, Travis J. Pathogenesis of periodontitis: a major arginine-specific cysteine proteinase from Porphyromonas gingivalis induces vascular permeability enhancement through activation of the kallikrein/kinin pathway. J Clin Invest 1994; 94(1): 361-7.
114. Monteiro AC, Scovino A, Raposo S, et al. Kinin danger signals proteolytically released by gingipain induce Fimbriae-specific IFNgammaand IL-17-producing T cells in mice infected intramucosally with Porphyromonas gingivalis. J Immunol 2009; 183(6): 3700-11
115. Aliberti J, Viola JP, Vieira-de-Abreu A, Bozza PT, Sher A, Scharfstein J. Cutting edge: bradykinin induces IL-12 production by dendritic cells: a danger signal that drives Th1 polarization. J Immunol 2003; 170(11): 5349-53
116. Monteiro AC, Schmitz V, Svensjo E, et al. Cooperative activation of TLR2 and bradykinin B2 receptor is required for induction of type 1 immunity in a mouse model of subcutaneous infection by Trypanosoma cruzi. J Immunol 2006; 177(9): 6325-35
117. Monteiro AC, Schmitz V, Morrot A, et al. Bradykinin B2 Receptors of dendritic cells, acting as sensors of kinins proteolytically released by Trypanosoma cruzi, are critical for the development of protective type-1 responses. PLoS Pathog 2007; 3(11): e185.
118. Schmitz V, Svensjö E, Serra RR, Teixeira MM, Scharfstein J. Proteolytic generation of kinins in tissues infected by Trypanosoma cruzi depends on CXC chemokine secretion by macrophages activated via Toll-like 2 receptors. J Leukoc Biol 2009; 85(6): 1005-14.
119. Scharfstein J, Schmitz V, Svensjö E, Granato A, Monteiro AC. Kininogens coordinate adaptive immunity through the proteolytic release of bradykinin, an endogenous danger signal driving dendritic cell maturation. Scand J Immunol 2007; 66(2-3): 128-36.
120. Kaman WE, Wolterink AF, Bader M, Boele LC, van der Kleij D. The bradykinin B2 receptor in the early immune response against Listeria infection. Med Microbiol Immunol 2009; 198(1): 39-46.
121. Del Nery E, Juliano MA, Lima AP, et al. Kininogenase activity by the major cysteinyl proteinase (cruzipain) from Trypanosoma cruzi. J Biol Chem 1997; 272: 25713-18.
122. Stoka V, Nycander M, Lenarcic B, et al. Inhibition of cruzipain, the major cysteine proteinase of the protozoan parasite, Trypanosoma cruzi, by proteinase inhibitors of the cystatin superfamily. FEBS Lett 1995; 370: 101-4.
123. Lima AP, Almeida IL, Tersariol I, et al. Heparan sulfate modulates kinin release by Trypanosoma cruzi through the activity of cruzipain. J Biol Chem 2002; 2277: 5875-81.
124. 2+ and cell migration. J Leukoc Biol 2007; 81(6): 1445-54.
125. Shortman K, Naik SH. Steady-state and inflammatory dendritic cell development. Nat Rev 2007; 7: 19-30.
126. Morrot A, Strickland DK, Higuchi M de L, Reis M, Pedrosa R, Scharfstein J. Human T cell responses against the major cysteine proteinase (cruzipain) of Trypanosoma cruzi: role of the multifunctional 2-macroglobulin receptor in antigen presentation by monocytes. Internat Immunol 1997; 9(6): 825-834.
127. Benítez-Hernández I, Méndez-Enríquez E, Ostoa P, et al. Proteolytic cleavage of chemokines by Trypanosoma cruzi's cruzipain inhibits chemokine functions by promoting the generation of antagonists. Immunobiol 2009; in press.
128. Turk B, Stoka V, Turk V, Johansson G, Cazzulo JJ, Björk I. Highmolecular-weight kininogen binds two molecules of cysteine proteinases with different rate constants. FEBS Lett 1996; 391(1-2): 109-12.
129. Waghabi MC, Coutinho CM, Soeiro MN, et al. Increased Trypanosoma cruzi invasion and heart fibrosis associated with high transforming growth factor beta levels in mice deficient in alpha(2) macroglobulin. Infect Immun 2002; 70(9): 5115-23.